3MM Stock Chart & Stats
€1.76
€0.04(2.63%)
At close: 4:00 PM EDT
€1.76
€0.04(2.63%)
Day’s Range― - ―
52-Week Range€0.77 - €2.20
Previous CloseN/A
Volume0.00
Average Volume (3M)67.00
Market Cap
€10.79M
Enterprise Value€42.82
Total Cash (Recent Filing)€1.34M
Total Debt (Recent Filing)€19.00M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Sep 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding14,609,619
10 Day Avg. Volume202
30 Day Avg. Volume67
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.87
Price to Sales (P/S)3.81
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€6.60M
Bulls Say, Bears Say
Bulls Say
Rare-disease SpecializationA focused rare-disease strategy can support specialized expertise, differentiated formulations, and targeted commercial execution. Concentrating on clinically defined conditions may help the company build durable product knowledge and relationships in markets where treatment options are limited.
Improving Gross ProfitabilityThe shift to positive gross margin indicates that product economics improved at the gross-profit level, which is an important foundation for future operating leverage. If maintained as sales develop, better unit economics could help reduce the gap between revenue growth and eventual profitability.
Multiple Commercialization ChannelsCombining direct or distributor-based product sales with licensing and partner arrangements gives Advicenne more than one route to monetize its therapies. This model can support geographic expansion and leverage partners’ commercial capabilities while retaining potential royalty or milestone economics.
Bears Say
Negative Equity And Fragile LeverageSustained negative equity materially weakens the capital structure and limits financial flexibility. Debt that remains significant relative to assets can increase solvency pressure and restrict the company’s ability to fund development, absorb setbacks, or negotiate from a position of strength.
Persistent Cash BurnRepeated negative operating and free cash flow means the business has not yet funded operations internally. Continued deterioration in 2025 increases dependence on external financing, making execution more sensitive to capital availability and potentially constraining investment in products and expansion.
Unprofitable And Volatile Revenue BaseA small, volatile revenue base combined with persistent operating and net losses indicates that commercial scale has not yet translated into a sustainable earnings model. Negative 2025 growth further raises the risk that fixed costs and development spending will remain unsupported by recurring sales.
Advicenne SA News
3MM FAQ
What was Advicenne SA’s price range in the past 12 months?
Advicenne SA lowest stock price was €0.77 and its highest was €2.20 in the past 12 months.
What is Advicenne SA’s market cap?
Advicenne SA’s market cap is €10.79M.
When is Advicenne SA’s upcoming earnings report date?
Advicenne SA’s upcoming earnings report date is Sep 17, 2026 which is today.
How were Advicenne SA’s earnings last quarter?
Advicenne SA released its earnings results on Mar 26, 2026. The company reported -€0.314 earnings per share for the quarter.
Is Advicenne SA overvalued?
According to Wall Street analysts Advicenne SA’s price is currently Overvalued.
Does Advicenne SA pay dividends?
Advicenne SA does not currently pay dividends.
What is Advicenne SA’s EPS estimate?
Advicenne SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advicenne SA have?
Advicenne SA has 14,609,619 shares outstanding.
What happened to Advicenne SA’s price movement after its last earnings report?
Advicenne SA reported an EPS of -€0.314 in its last earnings report. Following the earnings report the stock price went up 15.881%.
Which hedge fund is a major shareholder of Advicenne SA?
Currently, no hedge funds are holding shares in DE:3MM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advicenne SA
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular acidosis and cystinuria. Established in 2007, Advicenne S.A. maintains its principal offices in Paris, France.